Exscientia (NASDAQ:EXAI – Get Rating) and SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Exscientia and SOPHiA GENETICS's gross revenue, earnings per share (EPS) and valuation.

Exscientia has higher earnings, but lower revenue than SOPHiA GENETICS. Exscientia is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Profitability

Institutional and Insider Ownership

22.4% of Exscientia shares are owned by institutional investors. Comparatively, 31.0% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Exscientia and SOPHiA GENETICS, as provided by MarketBeat.

Exscientia presently has a consensus target price of $15.67, indicating a potential upside of 150.67%. SOPHiA GENETICS has a consensus target price of $6.67, indicating a potential upside of 115.05%. Given Exscientia's higher probable upside, research analysts plainly believe Exscientia is more favorable than SOPHiA GENETICS.

Volatility and Risk

Exscientia has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Summary

SOPHiA GENETICS beats Exscientia on 7 of the 12 factors compared between the two stocks.

About Exscientia

(Get Rating)

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

About SOPHiA GENETICS

(Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.